A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA.

Although a modestly significant ( p = 0.044) difference in MAS changes at day 30 may suffer from multiple comparisons, the present results may indicate the superior efficacy at day 30, since we set MAS changes up to 30 days or 60 days in AUCs as co-primary outcomes from the start (ClinicalTrials.gov NCT01910363 ).

also in 257 other papers

As depicted in Figure 4 , the A2NTX group, but not the OnaA group, showed highly significant functional improvements at day 60 in the within-group comparison before and after the treatment.

also in 132,142 other papers